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Introduction: Proton therapy is a radiation treatment method growing around the 
world. This is mainly due to the protons ability to deposit dose more conformal 
compared to conventional photon therapy. Protons also differ in terms of biological 
effect compared to photons for the same physical dose. To account for this increased 
relative biological effectiveness (RBE), a constant RBE of 1.1 is applied in clinical 
proton therapy treatment planning, i.e. approximately 10% lower physical dose is given 
to the tumor if proton therapy is used. It is however known that the RBE is not constant, 
and is dependent on e.g. the linear energy transfer (LET), physical dose and tissue type. 
By using biological optimization the tumor may get a homogenous biological dose 
distribution, and prevent over- and under dosage to healthy tissue and the tumor 
volume. Variable RBE models can be used to optimize a treatment plan with respect to 
RBE-weighted dose, but these are not yet available in commercial treatment planning 
systems.  
The aim of this study was to implement a method for optimization of treatment plans 
with respect to both biological and physical dose, and further use this to analyze the 
differences in physical and biological dose distributions depending on the optimization 
strategies applied.   
Methods: The FLUKA Monte Carlo code was used together with a prototype 
optimization software to calculate and optimize RBE weighted dose distribution for 
proton treatment plans. Treatment plan information from the TPS, such as beam 
energies and positions, was exported and translated to fit the format of the optimizer. 
The mathematical formulation of three RBE models were also included in the 
biological dose calculation and optimization; the Rørvik model, the Unkelbach model 
and the Wedenberg model. These models vary in which parameters they are based on, 
and therefore provide a good basis for comparison. The different treatment plans 
consisted of a water phantom with a cubic planning target volume (PTV), three plans 






clinical patient plan. The results from the optimization were verified by running a 
FLUKA simulation with the original plan, optimizing the result, and then a final 
FLUKA simulation to verify the dose distribution. The physical dose distributions from 
the RBE models were compared and a single field optimization of a patient plan was 
also performed to analyze the dose distribution. 
Results: The results from the optimizer showed a homogenous RBE-weighted dose 
distribution for the different treatment plans and RBE-models. The PTV for all plans 
received the prescribed dose when the optimized result was verified. Promising results 
was also achieved from the patient plan where the optimizer provided a relatively even 
dose distribution although with some discrepancies. The calculations of physical dose 
distribution from the variable RBE-optimized plans showed in general lower physical 
dose to the PTV, compared to plans optimized with a constant RBE of 1.1. Physical 
dose distribution from the plan optimized with respect to the Wedenberg model was 
also observed to be lower than plans optimized with respect to both the Unkelbach- and 
Rørvik model. The latter two models showed similar physical dose distributions. 
Conclusions: A method for the use of a prototype optimization algorithm was 
integrated into an existing Monte Carlo based dose calculation framework. The 
implementation was applied for different RBE models, where the physical dose 
distributions from the RBE models were compared. Applying variable RBE-models in 
treatment planning may lead to lower physical dose to the target, thus preventing under- 
and overdosage to the tumor and surrounding tissue, respectively. Differences between 
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1.1 Radiation Therapy 
In 2016, over 32,000 people were diagnosed with cancer in Norway, and the number 
of incidents is growing each year [1]. Typically, more than half of these patients receive 
radiotherapy during their treatment and the use of radiation treatment is therefore one 
of the most important modalities in cancer therapy [2]. The goal of radiotherapy is to 
deliver as much dose to the tumor volume as possible, while at the same time 
minimizing the dose to the healthy tissue. 
The idea of using radiation therapeutically came from E. H. Grubbe in 1896 after 
suffering X-ray dermatitis because of radiation exposure [3]. He consulted with a 
doctor about the inflammation on his hand, who saw the beneficial therapeutic 
application of radiation and urged him to start treating patients with the radiation. Two 
patients were entrusted to Grubbe and only 60 days after Röntgen had announced his 
discovery of the X-rays, Grubbe had treated both a neoplastic and an inflammatory 
lesion in a factory in Chicago.  
In recent years, radiotherapy has come a long way from its first applications. One of 
the big marks in radiotherapy came when computed tomography (CT) was introduced 
in 1971 by Hounsfield, which gradually shifted the radiation treatment planning from 
a 2D perspective to 3D [4]. In the 1990s, with multileaf collimators and computer 
driven algorithms, radiotherapy was revolutionized, and accurate dose distribution to a 
3D target became possible. The next leap in radiotherapy came in the early 2000s, with 
intensity modulated radiotherapy (IMRT). IMRT modulates the intensity of the photon 
beam during fractionating by using inverse dose planning in a treatment planning 
system (TPS) [4].  
Treatment with highly energetic photons is the most common form of radiation therapy, 
but has its limitations with respect to dose conformity. Particle therapy, i.e. radiation 
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therapy with protons and heavier ions, is a treatment method growing around the globe, 
and consists of using the unique qualities of accelerated charged particles [5]. Protons 
and heavy charged particles have the ability to deposit their radiation in a more 
concentrated region compared to photons, and thereby limiting radiation dose to 
healthy tissue. This is the main motivation for therapeutic use of these particles [6]. 
1.2 Proton Therapy 
In 1946, Robert R. Wilson suggested the use of protons in therapeutic radiation 
treatment, because of its depth-dose characteristics (Figure 1.1b) [7]. In 1954, only 
eight years after Wilsons had written about the therapeutic advantages of proton 
therapy it was applied by researchers at Lawrence Berkley National Laboratory in 
California to treat a series of patients [8]. Because treatment with protons was novel 
and highly experimental at the time, the treatments were performed in physics 
laboratories [9]. 
In 1990, Loma Linda University Medical Center in California USA became the first 
hospital with a proton therapy facility, and it was not until ten years later before another 
hospital-based treatment facility opened [10]. A reason for the modest interest in 
building proton centers worldwide is the high cost and reward compared to regular 
photon therapy. It has been calculated that treatment at a proton-only center is 3.2 times 
more expensive than treatment with photon therapy [11]. Today, 68 proton therapy 
centers are clinically active worldwide, and many more are under planning, including 
two centers in Norway [12]. According to the Particle Therapy Co-Operative Group 
(www.ptcog.ch), close to 175,000 patients worldwide had been treated with particle 




Figure 1.1 (a) Linear energy transfer (LET) of protons vs energy of the 
proton beam. (b) Depth dose curves for photons (dashed line) and protons 
(solid line). The dotted lines are representing a spread out Bragg peak 
(SOBP) for protons [13]. 
The therapeutic advantage of protons compared to photons is their energy deposition 
in matter.  Protons will slow down as they go through matter, and the energy deposition 
from the protons will increase with the decreasing velocity. This results in a maximum 
dose deposition at end of the particle’s range, called the Bragg peak (Figure 1.1b). 
Photons, on the other hand, deposits most of their energy at the beginning of their path, 
followed by a decrease in dose deposition further into the matter [10].  
The linear energy transfer (LET), describes the rate of energy loss per unit length along 
a particle track, and is typically reported in units of keV/μm. The LET depends on the 
particle energy (Figure 1.1a) and decreases while the energy of proton increases [13]. 
Figure 1.1b shows the depth dose curves for photons, protons and a manipulation of 
multiple proton energies called the spread out Bragg peak (SOBP).  
In addition to the different dose deposition between protons and photons, the biological 
effects, e.g. their ability to kill or inactivate cells, differs due to the different particle-
interaction processes. To compensate for this difference, the relative biological 
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effectiveness (RBE) was introduced, defined as the ratio between the dose of a 
reference radiation and of protons, when both modalities produced the same biological 
effect [2]. To account for the increased RBE of protons compared to photons, the 
physical dose is scaled by a constant and generic RBE-factor of 1.1 in treatment 
planning for clinical proton therapy [14]. However, experimental data, mainly from in 
vitro cell irradiation experiments have shown that the RBE of protons is not constant 
and depends on many physical and biological parameters, such as the physical dose, 
the linear energy transfer (LET) and the photon (𝛼 𝛽⁄ )-ratio of the Linear Quadratic 
(LQ) model [15]. Overall, the experimental data indicates that the assumption of a 
constant RBE of 1.1 might be too low, especially towards the end of the protons range 
[14]. 
1.3 Motivation 
The application of a constant RBE of 1.1 (RBE1.1) in clinical proton therapy is a 
simplification which in principle can lead to both under- and overdosage of the tumor, 
as well as higher doses to the surrounding healthy tissue than anticipated. The use of 
variable RBE models in treatment planning and optimization, so-called biological 
optimization, could therefore increase the quality of treatment plans for proton therapy 
[16]. For carbon ion therapy, biological optimization is already implemented clinically, 
however, the RBE effects of carbon ions are larger than the RBE effects of protons 
[14].  A reason for still using the constant RBE in proton therapy is the uncertainty and 
complexity introduced by the biological models, and that biological optimization is not 
currently available in commercial systems for treatment planning. It is therefore of 
interest to explore how patients can get a more accurate dose distribution when 
accounting for the variable biological effects, and also quantify the amount of over- 
and underdosage to the target volume which can occur using RBE1.1.  This can be done 
by optimizing a treatment plan with respect to multiple a variable RBE model and 
compare to an RBE1.1 optimized treatment plan. 
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The objective of this study was therefore to implement a system for re-optimization of 
existing proton treatment plans using variable RBE-models, make it compatible with 
the in-house tools used for dose verification, and to analyze the differences in physical- 
and biological dose distributions depending on the optimization strategies applied. The 
system is  based on the FLUKA Monte Carlo (MC) code [17, 18], together with Eclipse 
treatment planning system (TPS) (Varian Medical Systems, Palo Alto, CA, USA) and 
a prototype optimization algorithm [19].  
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2. Physics of particle therapy 
High energetic photons and ions are able to ionize the irradiated matter, ejecting 
electrons from the target atoms [20]. Particle- and photon therapy differ significantly 
in how the dose is deposited on a micrometer level. These differences have shown to 
give rise to large differences in biological effect from the same macroscopic dose from 
photons and protons [9]. This chapter covers the basic interactions of protons with 
matter, with an emphasis on physical quantities important for modelling of biological 
effectiveness. 
2.1 Proton interactions with matter 
Heavy charged particles, i.e. particles with mass greater than the electron, have three 
main ways of interacting with matter: (a) They are slowed down by Coulomb 
interaction with the atomic electrons, (b) deflected by Coulomb interaction with nuclei, 
and (c) undergo nuclear interactions with a nucleus [6, 10]. The interactions are 




Figure 2.1 Illustration of the three main interactions a proton undergoes: (a) 
inelastic interactions with the atomic electron, (b) Coulomb-scattering and (c) 




2.1.1 Inelastic interactions with the atomic electron 
The primary source of energy loss is the Coulomb interaction with the atomic electrons 
(Figure 2.1a). A proton will lose a small fraction of its energy to an atomic electron 
either by excitation of the electron to a higher shell or by ionization of the electron, 
which removes it completely [22]. Since the mass of a proton is far greater than the 
mass of an electron, the proton will not deviate much from its original trajectory after 
the interaction. The majority of secondary electrons made from this interaction will 
only travel a short distance from the proton-path while ionizing and depositing energy. 
These electrons are called delta rays [10].  
The complex interaction between the charged particle and atomic electrons represents 
the electronic stopping power and is described by the Bethe-Bloch formula [23, 24]: 
where 𝑑𝐸 is the energy loss over a track segment 𝑑𝑥. The remaining parameters are 
described in Table 2.1. 
Table 2.1 Description of the variables in the Bethe Bloch equation 
Variable Description  Variable Description 
𝑵𝒂 Avogadro’s number  𝑰 Mean excitation 
potential 
𝑴𝒆 Atomic mass  𝝆 Density of the absorbing 
material 
𝒁 Atomic number of the 
material 
 𝑾𝒎𝒂𝒙 Maximum energy 
transfer from a single 
collision 
𝑨 Atomic mass of 
material 
 𝜸 Lorentz-factor 
𝒛 Charge of the incident 
particle 
 𝜹 Density correction 
𝜷 = 𝒗 𝒄⁄  Relativistic velocity  𝑪 Shell correction 
𝒗 Speed of incident 
particle 
 𝒄 Speed of light in vacuum 
𝒓𝒆 Classical electron 
radius 
























The Bethe-Block formula describes how much energy, 𝑑𝐸, a charged particle loses 
along a track segment 𝑑𝑥, in matter. The last two terms of the Bethe-Block equation is 
correction terms which includes quantum mechanics and relativistic effects, and 
requires very high or very low energies to be considered [21]. An important aspect of 
the Bethe-Block is how the projectiles characteristics affect the energy loss. It can be 
seen that the energy loss is proportional to the inverse square of the velocity, and the 
square of the ion-charge. It is not dependent on the mass of the projectile, but relies 
heavily on the absorber’s mass density [21].  
2.1.2 Coulomb scattering 
If the proton passes close to the nucleus, it will be deflected by the Coulomb repulsion 
of the positive charged nucleus. This is referred to as Coulomb scattering (Figure 2.1b). 
Although the deflection of each interaction might be small, the sum of all the 
deflections can lead to a high lateral spreading of protons [10]. It therefore is necessary 
to take into account the Coulomb scattering in dose calculations of dose distributions 
in phantoms or patients with treatment planning systems [21]. 
2.1.3 Nuclear interactions 
If the distance of approach between the nucleus and proton becomes too small, the 
proton may undergo nuclear interactions with the nuclei in form of scattering (Figure 
2.1c). Although the probability of scattering is small, it will increase with the number 
of nuclei in the target and with the energy of the proton. It is estimated that around 20% 
of protons with high energies undergo nuclear interactions [10]. Nuclear interactions 
can be defined as elastic or non-elastic. In an elastic nuclear interaction, the nucleus 
will only recoil and the total kinetic energy will be conserved. However, in non-elastic 
collisions, the target nucleus will absorb some of the kinetic energy and might undergo 
several nuclear interactions, such as disintegration, emission of prompt gamma rays 
etc. The recoil nucleus will be absorbed at the point of interactions, while the secondary 
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particles, protons and neutrons, will travel a relatively large distance and produce a 
halo of low dose around the beam [10]. 
2.1.4 Range straggling 
An important aspect of the stopping power is that it is only an average value for the 
energy loss per unit distance, and real life fluctuation will occur. This is known as 
energy-loss straggling, or range straggling [25]. A theory by Janni [26] postulates the 
standard deviation of range straggling as a percentage of the mean projected range. For 
light materials the range straggling for protons is about 1.2 %, and slightly higher for 
heavy materials [6]. 
2.1.5 Absorbed dose 
The absorbed dose D is the basic physical dose quantity and is used for all types of 
radiation and every type of geometry. The definition is quotient of energy 𝑑  ̅imparted 
from ionizing radiation to a matter of mass 𝑑𝑚. The dose is therefore given as 
The SI unit for absorbed dose is Gray (Gy), or J/kg [27]. The absorbed dose is 
insufficient when it comes to predicting probability of health effects resulting from 
unspecified conditions. The International Commission on Radiological Protection 
(ICRP) suggested weighting factors to account for the delayed stochastic effects [28]. 
In proton therapy, the terms physical dose and biological dose are used, where the 
physical dose equals the absorbed dose.  
2.1.6 Spread-out Bragg Peak 
The Bragg Peak (Figure 1.1b), is made up by the sum of the three proton interactions, 
and is where the proton deposits maximum energy [13]. The depth of the Bragg peak 









volume can be covered by a uniform dose along the beam axis. The plateau of the 
different energies is called the spread-out Bragg peak (SOBP) [29] (Figure 2.2). 
 
Figure 2.2: Manipulating several individual Bragg peaks to make a flat dose 









2.2 Linear energy transfer 
There is a difference between the amount of energy deposited in the medium by a 
charged particle and how the energy is absorbed by the medium [30]. To describe this 
difference, Zirkle [31] introduced the linear energy transfer (LET), and defined it as 
the energy, 𝑑𝐸, transferred from fast charged particles per unit length, 𝑑𝑥, of their 
paths, to the biological material in on near these paths [31]. The LET is normally given 
in the unit keV/μm, and can mathematically be written as: 
The LET of protons will increase inversely with the proton velocity. Because of this 
energy deposition, protons will lose energy at an increased rate further into a uniform 
medium, and therefore deposit more and more energy until they stop. The LET is 
therefore a measure of the rate of energy loss per unit length along a particle track and 
reflects the number of ionizations created along the track [13]. For protons, the LET is 
relatively low until the end of their range. Then, when the protons approach the end of 
their range, the LET rises drastically. This gives protons as well as other heavy charged 
particles, an advantage in that they deposits most of their energy at the end of their 
path. This property utilized in proton therapy treatment [13]. 
Most of the particle energy is lost due to the inelastic interaction with the atomic 
electrons, as described by the Bethe-Block formula (equation (2.1) although a small 
portion of the energy is converted to bremsstrahlung or long distance delta rays [30]. 
The LET with a cutoff energy to restrict the energy from delta rays is called the 
restricted LET, denoted 𝐿𝐸𝑇Δ. If no cutoff from the delta rays is considered, the LET 













From the original definition of LET, two different practical concepts are derived. The 
track-averaged LET (𝐿𝐸𝑇𝑡) and the dose-averaged LET (𝐿𝐸𝑇𝑑). When biological 
outcome is the focus of a study, the 𝐿𝐸𝑇𝑑 is generally the value used because it 
considers both LET and dose [32]. 𝐿𝐸𝑇𝑑 can be calculated as follows: 
where 𝑆𝑒𝑙(𝐸) is the electronic stopping power of a primary charged particle with kinetic 
energy 𝐸 and 𝐷(𝐸, 𝑧) is the absorbed dose contributed by a primary charged particle 
















3.1 Biological damage by radiation 
An important aspect of radiotherapy is to understand the damage radiation does to 
biological tissue. When radiation interacts with tissue, its energy will be converted and 
deposited in the tissue [33]. Observed radiation effects can broadly be classified into 
two groups, stochastic and non-stochastic effects. Stochastic effects occur randomly 
and the probability of incidents is decided by the dose. An example is cancer, which 
can occur without known exposure to radiation [34]. Most biological effects fall under 
non-stochastic effects, or deterministic effects. There are three qualities that 
categorizes the deterministic effect: A minimum dose must be exceeded for observable 
effect of the radiation, the magnitude of the effect grows with the dose, and there is a 
casual relationship between the radiation and the observable effects [34]. A comparison 
between the two effects is given Figure 3.1. 
 




When a cell is exposed to radiation, the most vulnerable material is the DNA [35]. Cell 
death induced by radiation is therefore mainly attributed to radiation damage of the 
DNA. Radiation can damage the DNA in two ways, either by direct action or by 
indirect action. With direct action, the radiation hits the DNA directly and disrupts the 
molecular structure. This is the lead process for radiation with high LET, such as 𝛼-
particles and neutrons, high energy doses, and low energy (i.e. high LET) heavy 
charged particles in general [36]. When radiation ionizes the water, it leads to chemical 
reactions that threaten the DNA with highly reactive radicals. This is indirect radiation 
effect on the DNA. For low LET radiation, the most common radiation effect is through 
the delta-rays creating free radicals, while direct action is more relevant for higher LET 
radiation [6]. 
 
Figure 3.2 Direct and indirect action of radiation [1] 
The most common damages to the DNA from radiation are base damage, single strand 
break (SSB), and double strand breaks (DSB). The DSB is often considered the critical 
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lesion and is believed to be the main cause of late and early effects from ionizing 
radiation. An even more complex damage occurs when there are two or more types of 
lesions nearby in the same DNA. These clustered lesions are very difficult to repair, 
and is postulated to be responsible for lethal and mutagenic effects of ionizing radiation 
[13]. 
When the DNA is damaged, it will try to repair itself and failure to repair itself gives 
rise to mutations and chromosomal abnormalities. An important strategy to avoid and 
guard against the mutations is cell death [37]. The most commonly applied model 
which describe the radiobiological effects and cell death is called the linear quadratic 
model (LQ-model). It describes the surviving fraction S of cells after they are irradiated 
with a dose D, and is given by: 
Here 𝛼 and 𝛽 are tissue specific parameters. The parameters can be correlated to 
respectively single track events and double track events; at low doses the 𝛼 will 
dominate, while at higher doses, more strands on the DNA will break and the 𝛽 will 
dominate [2, 38].  
3.2 Relative biological effectiveness - RBE 
The relative biological effectiveness (RBE) of protons is the ratio of the dose of a 
reference radiation, gamma or MeV X-rays, to protons, needed to produce the same 
biological effect [2]. The effect can be quantified by measuring a biological endpoint 
of irradiated cells or tissue, like the median lethal dose or a specific clonogenic survival 
level, i.e. a certain fraction of cells surviving an irradiation [13]. The RBE is 
mathematically defined as:  






𝑑𝑜𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛






when the dose of the reference radiation and of the test radiation results in the same 
biological effect. 
For proton therapy, clinical treatment planning is performed with an RBE of 1.1. 
However, it is widely agreed upon that the RBE is not constant, and in many instances 
higher than 1.1, especially in the distal part where the LET is high [14]. To account for 
the difference in RBE between particles and photons, treatment plans in particle 
therapy can be optimized applying the RBE-weighted dose (𝑅𝑅𝐵𝐸), also called 
biological dose: 
where, 𝐷 is the physical dose. In particle therapy, the biological dose is given in 
Gy(RBE), replacing the previous used dose-equivalent and cobalt-Gray equivalent.  
In spite of many years of research, the RBE is still the main source of uncertainties 
when it comes to dose estimation in charged particle therapy [14]. As mentioned, a 
constant RBE of 1.1 is used clinically in proton therapy, but it is acknowledged that the 
variation in RBE ideally should be corrected for, especially around the distal part of 
the SOBP and in the distal dose falloff. This increase of RBE also causes a shift in the 
biological effective range and enhances the effective beam range and from Figure 3.3  
it can be seen that the shift in range can be up to several millimeters [14]. A reason for 
why this generic RBE-value is still in use is due to the lack of biological input 
parameters. This leads to lack of RBE-values in all tissues in the treatment planning 
process, and therefore the generic RBE is still recommended for clinical use [39]. 






Figure 3.3 Biological range extension for proton, where the blue line is the 
physical dose, the dashed orange line is the biological dose with constant 
RBE of 1.1 and solid orange line is the biological dose calculated using a 
variable RBE model (the LEMIV) [14]. 
In vitro studies of the RBE show a bell shaped dependency of the LET-value (Figure 
3.4), and also a dependence on the particle charge [14]. It is also been shown that the 
RBE dependence on several other different factors, which often are independent of 
each other. These factors are for example dose, biological endpoint, tissue type, dose, 
and proliferation i.e. the rate of repopulation [14]. 
As mentioned above, the RBE of proton increases towards the end of the range, which 
has been reported by in vitro cell survival experiments. From the experiments, 
depending on different parameters, it can be seen that RBE increase from around 1.0 
and 1.1 in the entrance region, to about 1.3 in the Bragg-peak and 1.6 in the falloff 
region [40]. However, the absolute values of RBE has been shown to be strongly 
dependent (inversely proportional) on dose [40], and estimates of RBE also varies 
significantly between different RBE models. The explanation for this rise in RBE is 
that the LET increases towards the end of the particle range. The correlation can be 





Figure 3.4 Relationship between RBE for cell killing and LET [2]. The RBE 
has been calculated at surviving fraction (SF) levels of 0.8, 0.1 and 0.01 for 
helium-ions. 
3.2.1 Biophysical models for the prediction of the RBE 
There are several different models for calculating RBE, and most of them are based on 
the LQ-model. The derivation of a generic expression of the RBE from the LQ-model 
is described in the following. From the LQ-model (equation (3.1)), the photon and 
proton dose at the same survival level is described as follows: 
where 𝐷 is the dose, and all quantities with subscript 𝑥 represents photon radiation, 
while the others represents proton radiation. Solving this secondary equation for the 
positive roots of 𝐷𝑥 gives: 








From this, together with the definition of the RBE, a generalized expression for the 
RBE can be given as 
 
Here, 𝐷/𝐷𝑥 is the physical dose and, 𝛼/𝛼𝑥 and 𝛽/𝛽𝑥   is biological tissue-parameters 
of the LQ-model, for protons and photons, respectively [15, 41]. Further, by evaluating 
the upper and lower physical dose limits, an expression for the extreme RBE at low 
and high doses can be found [42, 43]: 
Equation (3.6) can therefore also be written as 
While all LQ-based RBE models have equation (3.9) in common, they differ in the 
definition of 𝑅𝐵𝐸𝑚𝑖𝑛 and 𝑅𝐵𝐸𝑚𝑎𝑥 [44]. The RBE models which have been applied in 
this project are described in chapter 5.4. 


































































𝑅𝐵𝐸 = 𝑅𝐵𝐸𝑚𝑖𝑛 = √𝛽 𝛽𝑥⁄  . (3.8) 






























4. Treatment planning 
The aim of treatment planning is to optimize the dose distribution to a target volume, 
and minimize the dose for the surrounding normal tissues. The planning is done by a 
simulation software also known as a treatment planning system (TPS), which estimates 
the treatment delivery system to deliver a uniform dose to the target volume [45]. 
With radiotherapy as any other medical procedure, there is a balance between risk and 
benefit [2]. Treatment planning is therefore an act between maximizing the probability 
of curing the patient (Tumor Control Probability), and minimizing the probability of 
serious side effects (Normal Tissue Complication Probability) [6].  
4.1.1 Uncertainties 
There are always uncertainties when it comes to dose and dose distribution. An aim, 
suggested by international regulatory bodies, is that the delivered dose should be within 
2.5% of the prescribed dose [9]. Dose calculations are done routinely using analytical 
algorithms in traditional photon therapy, but have shortcomings in proton therapy. 
Monte Carlo (MC) simulations is considered the gold standard in dose calculations, 
and although previously deemed too slow for clinical use, recently achieved the 
efficiency that can make them suitable for clinical treatment planning [9]. 
4.2 The treatment planning process 
The process of planning and improving cancer treatment relies on modelling.  A model 
which accurately describes the transport of the beam through the patient is needed, as 
well as a model that describes the biological consequences of the beam. This includes 




The first step of treatment planning is to acquire images (normally computed 
tomography (CT)) of the patient to review the extent of the tumor, and also localize 
organs at risk (OAR) [45]. 
The second step in the treatment planning process is segmentation. From the images, 
medical doctors and physicist define the volumes of the patient, such as the target 
volume and the OARs [45]. The most important volume is the planned target volume 
(PTV), to which the prescribed dose should be delivered. The PTV is a delineation of 
the tumor volume, with safety margins according to the International Commission on 
Radiation Units (ICRU). The medical doctor will first define where the visible tumor 
is in a Gross Tumor Volume (GTV), and then expanding it into a Clinical Target 
Volume (CTV), to account for the invisible spread of cancer cells. The last step in the 
delineation is to account for the uncertainties in the dose delivery and target movement 
into the PTV [6]. Any OARs are also delineated and prescribed a maximum dose in 
this process [45]. 
4.3 Treatment planning techniques 
In clinical particle therapy, there are two main techniques to deliver homogenous dose 
to a target, passive scattering and active scanning, the latter also termed pencil beam 
scanning (PBS). There are advantages and disadvantages for both techniques, but 
scanning has properties which makes it the better option when it comes to optimize 
dose to a target, and is the technique implemented in all new proton therapy centers. 
PBS is a technique that moves a beam of charged particles over a target volume and 
can be seen in Figure 4.1. Different properties can be modulated during the scanning, 
as position, size, energy (and thus range) and intensity of the beam. A specific beam 
setup is known as a spot. Magnets are used to manipulate the beam position across the 




Figure 4.1 The technique of pencil beam scanning [47]. The dipole magnets 
manipulate the beam to the shape of the tumor. 
Intensity modulated proton therapy (IMPT) is a treatment technique which delivers a 
non-uniform dose distribution in each treatment field. The process begins with the 
desired dose distribution, and using algorithms to arrive with specification of the 
required dose fluence. This way of planning is called inverse planning [48]. Intensity-
modulation methods achieve the highest conformity of proton dose distribution to the 
target volume and spare most of the healthy tissue. The beam will change energy and 
intensity to control the dose to a point. The most common technique when it comes to 
IMPT is the 3D modulation method, where different Bragg peak spots are placed in the 
volume and are all individual weighted [6]. 
4.4 Monte-Carlo simulations 
MC simulations take into account the physics and interaction of particle-by-particle by 
using theoretical models or experimental cross section data. Tissue inhomogeneity is 
also considered in the MC simulation, by using parameters like material properties, 
atomic elemental composition, electron density, and mass density. One of the main 
advantages of these codes is that they can be used for as for dose validation purposes. 
Another advantage is that it can simulate the different components on the treatment 
head and extract parameterized phase spaces for complex beam delivery systems. 
Although the main MC codes (FLUKA, GEANT4 and MCNPX) were initially 
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designed for particle and nuclear physics use, they have been successfully integrated 
into the field of particle therapy [45]. 
How accurate the output from a MC-simulation is, depend on the number of particles. 
The uncertainty for a simulation with N events is therefore proportional to 1/√𝑁 [6]. 
4.5 Optimization problem 
For optimization methods, limitations and treatment goals need to be defined 
mathematically, respectively called constraints and objectives. The image data from 
the patient is therefore partitioned into volumes called voxels, which then includes the 
necessary data, as OAR and other tissue volumes. These voxels are further made into 
geometric objects called region of interest (ROI).  
The total dose from an IMPT field is the sum of all distributions from the static pencil 
beams at various positions along the particle track. The dose to voxel 𝑖 from pencil 
beam 𝑗 , can be written as 
where 𝑥 is the relative weight of beam  𝑗. The weighting variable needs to be 
determined in the treatment planning. Since thousands to tens of thousands pencil 
beams are used, mathematical optimization methods are used in IMPT. The output of 
the optimization is called the fluency map, and is a set of the beam weight distributions. 
An objective for voxels or volumes can be defined in the plan, and these are expressed 
in objective functions. An objective function which is widely used is the quadratic 
penalty function. This typically aims at minimizing the volume, within the OAR, that 
exceeds the maximum tolerance dose  𝐷𝑚𝑎𝑥. It is given by: 
 𝑑𝑖 =  ∑ 𝑥𝑗 ∙ 𝐷𝑖𝑗
𝑗
 (4.1) 









where 𝐻 is the Heavyside function which is zero for negative values and one for 
positive values. Similarly, there are quadratic functions that minimize tumor volumes 
that which receives less than a minimum dose 𝐷𝑚𝑖𝑛. Another constraint may be that 
every voxel in the ROI should be between a minimum dose and a maximum dose, 
which would lead to the hard constraint of: 
A problem with constraints and objectives is that they are often in direct conflict with 
each other in clinical situations. The solution to this problem is often to rewrite the 
constraint as an objective and change the different weightings for the objectives. An 
example of a conflict is when a target is not completely radiated because a critical 
structure lies next to it. The solution is to minimize the dose to the OAR that exceeds 
the dose limit instead of enforcing the dose around to be below the maximum limit. 
Such an objective is called a soft constraint [6]. 
4.6 Biological optimization 
Optimizing a treatment plan with respect to biological dose with variable RBE models 
is a growing topic in proton therapy. The limited ability to predict RBE distributions is 
one of the reasons why a constant RBE of 1.1 is used in clinical practice [49]. When 
RBE calculations are integrated into the optimization process, computational 
requirements becomes an issue, because the RBE is calculated for each iteration [16].  
The non-constant RBE value causes a dilemma when it comes to treatment planning, 
especially for IMPT. A higher RBE value than expected will lead to higher dose and 
more normal tissue complications. LET-hotspots may also occur in critical structures 
due to the physics and dose planning. Because of these uncertainties, RBE-based 
IMPT-planning is not used in clinical therapy yet [50]. 
 𝐷
𝑚𝑖𝑛 ≤ 𝑑𝑖 ≤ 𝐷





The first step in biological optimization is defining an RBE-model for the RBE and 
biological dose. In this thesis, we have focused on three models described in detail in 
chapter 5.4. These models are dependent on the LET and tissue specific parameters 
within a target volume or OARs. As LET varies spatially within the patient, LET 
calculations are needed for the RBE-models. With all the parameters, a new objective 
function can be made, similar to the one described in section 4.5, only with respect to 
RBE-weighted dose, rather than physical dose. This can be done by two objectives; 




5. Materials and Methods 
This chapter will describe the process of re-optimizing an existing treatment plan with 
respect to different biological models. An overview of the process is given in Figure 
5.1 with the descriptions found in Appendix A  In short, the information about the 
treatment plan, optimized with RBE1.1 from the Eclipse treatment planning system, 
were modified into a format usable as input in the FLUKA MC code. Then, MC 
simulations were run, and the output from the MC-simulation was directly used in a 
prototype optimizer. The optimizer modifies the weighting of the individual pencil 
beams (PBs) in the existing plan, with respect to a biological model chosen by the user. 
A second FLUKA-simulation with the now biological optimized plan was performed 
to generate the final dose distributions.  
 
Figure 5.1 Flowchart of the re-optimization process. Explanation of the 





5.1.1 Eclipse treatment planning system 
The Varian Eclipse treatment planning system is used at the Haukeland University 
Hospital. It can create treatment plans for many different radiation treatment 
modalities, including proton therapy. The exported treatment plans are given in 
DICOM (Digital Imaging and Communications in Medicine)-format. DICOM is the 
standard format for storing information in medical imaging. 
5.1.2 Optimizer 
A prototype optimizer [19] was used to optimize the treatment plans. The optimization 
program used information about the pencil beams, information about the physical dose, 
the biological variables 𝛼 and 𝛽 from FLUKA, and a file with information about which 
voxels in the CT image to irradiate (i.e. to irradiate the PTV while avoiding OARs). 
The cell-line for the chosen biological model has to be manually imported into the 
program. The program will use all the above information to calculate the best weighting 
scheme for the plan, with respect to the biological model.  
The optimizer (written in C++) is currently only run by employing a shell script, i.e. 
not with a graphical user interface (GUI). The shell script offers multiple options for 
the optimization process such as cell-lines, options for constant RBE and conversion 
criteria. In this project, the result was deemed sufficient when the cost function was 
below 1% i.e. the percent change between each iteration was lower than 1. 
The optimizer is made for the FLUKA implementation of the Centro Nazionale di 
Adroterapia Oncologica (CNAO) beam line. Here, beams are sent into the patient from 
different angles by rotating the patient, while the beam always comes from the same 
direction (z-direction). This is not similar to Eclipse, which makes plans where the 
gantry is rotated. The script sort_dicom.py was therefore modified to provide beams 
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from z-direction. The files received from CNAO was made for carbon-ion therapy 
plans, but has been changed to fit proton therapy plans. 
5.1.3 FLUKA 
The FLUKA MC code [17, 18] was used together with its interface, FLUKA advanced 
interface (FLAIR) [51]. The FLUKA development version was used in this project, as 
the optimizer required output from this version of FLUKA. 
FLUKA can be used with several subscripts, where the ones used in this project were 
the source and fluscw routine. The source routine reads in information about the pencil 
beam and converts the information so it can be read by FLUKA. The fluscw routine 
(which in essence is a fluence weighter) enables scoring of the biological parameters 
by choice, as dose is given by fluence × LET /𝜌, where 𝜌 is the density of the material. 
Treatment planning systems calculate dose to water, and to enable direct comparisons 
we did the same, making the density of water, i.e. 1g/cm3. A table containing 𝛼 and 𝛽 
values is included in the fluscw routine, and multiplied with 𝑓𝑙𝑢𝑒𝑛𝑐𝑒 × 𝐿𝐸𝑇, to 
achieve the biological variables needed for biological dose. In FLAIR, the Hounsfield 
units in the CT image can be converted into material density and element composition 
[52, 53]. This results in the VOXEL-files used in the simulation. 
The statistical uncertainty is calculated by FLUKA, and is dependent of number of 
primaries used in each simulation. Since statistical errors of MC simulations is 
dependent on 1/√𝑁, where higher statistics would lead to lower uncertainties. In this 
work, the number of primary histories needed to achieve reasonable low uncertainties 
were evaluated in each separate scenario as this varies with the beam properties and 
the geometry used in the simulation. Typical number of primary histories ranged from 





5.1.4 3D Slicer 
3D Slicer [54] is an open software for medical imaging and informatics. Slicer reads 
DICOM-files and allows the user to create 2D-plots, and dose volume histograms 
(DVHs). The extension SlicerRT is needed for DVH calculations [55]. In this project, 
Slicer was mainly used to achieve data for DVHs. 
5.2 The optimization process 
5.2.1 Intital simulation before the optimization 
The first step is to convert the DICOM-files into a format which is readable for the 
FLUKA MC program. This was done by using modified scripts originally created by 
Lars Fredrik Fjæra [56]. The output from the conversion includes a FLUKA input file 
and a file with the preliminary information about the pencil beam. The output also 
includes the standard subroutine scripts needed for the FLUKA MC simulation, i.e. the 
source and fluscw routines. The modification made for this project consisted of 
changing the direction of the beam, so it always came from the same direction.  
The aforementioned FLUKA-files had to be modified to fulfill the requirements of the 
optimization program. The file containing information about the pencil beams was split 
into multiple files, one for each core, using a python script created for this master 
project. Previous simulations in the group had been done by rotating the beam and 
leaving the patient in the same position, however, the optimizer requires the beams to 
always come from the same direction, and instead rotate the patient. This lead to a 
modification of the scoring cards so that the patient and the region of interest (ROI) 
were rotated instead the beam. In order to obtain sufficient statistics during the 
simulation process, the optimizer requires the total number of simulated primaries to 
be 5000 times larger than the number of pencil beams i.e. 5000 primaries per spot. The 
exported output from the FLUKA simulations were the physical dose, 𝐷, as well as 𝛼𝐷 




5.2.2 The optimization process 
The next step is to use the optimizer to achieve an optimized plan with respect to the 
different biological models. The optimizer reads in physical dose, 𝛼𝐷 and √𝛽𝐷  event 
by event values from the initial FLUKA simulation, as well as information about the 
pencil beams and information about the location of the PTV and OARs. The different 
ROIs are achieved using the Python script HUchanger.py, which reads in the DICOM-
files, and defines the voxels that belongs in the PTV and OARs.  
The output from the optimizer includes information about the new pencil beam 
weights, and different plots for every 10th iteration. These plots include dose volume 
histograms (described in chapter 5.2.3), and dose distributions. Examples of these plots 
can be found for each treatment plan in Appendix D . 
5.2.3 Plan verification and plotting of the results 
Before running the FLUKA-simulation for dose-verification, the information about the 
new weighting achieved from the optimizer must be converted into a format readable 
by FLUKA. A Python-script was created for this purpose, which replaces the original 
weights with the newly optimized weights in the original treatment plan. For the 
FLUKA-simulation, the scripts and method from the original dose verification tool are 
used, except for the modified file with the pencil beam information, and a modified 
scoring card. The output from the FLUKA-simulation is converted back into DICOM-
format and plotted by using modified scripts originally made by Fjæra [56]. For the 
dose volume histograms (DVHs), the open source software 3D Slicer is used, while 
Python scripts are used for the 1D plots.  
A DVH evaluates the dose distribution in a volume of interest and can be defined as 
the summed volume of elements receiving dose in a specified dose interval, against a 
set of equally spaced dose intervals [25]. The most frequently used is the cumulative 
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DVH which display the amount of volume receiving a dose greater than, or equal to 
the given dose, plotted as a function of dose. Cumulative DVHs will be displayed in 
this project. 
For the cubic PTV in the water phantom, the different RBE-weighted doses were also 
compared to each other, when the plan was optimized with respect to physical dose 
(RBE = 1.0).  
5.3 Applied treatment plans 
The optimization process was first tested on a simple cubic PTV in water, before 
proceeding to a more complex L-shaped PTV shape in water. The L-shaped volume 
was chosen to detect potential errors in the beam and patient rotation. Finally, the 
optimizer was tested on a patient plan. 
5.3.1 Cubic PTV in water 
The plan for the water phantom was made in the Eclipse TPS for Johan Martin 
Søbstad’s master thesis [57]. The phantom is 30 × 30 × 30 cm3, and the region of 
interest is a PTV with a volume of 4 × 4 × 4 cm3 placed in the center. The phantom 
was initially prescribed a total dose of 2 Gy(𝑅𝐵𝐸1.1). An illustration can be seen in 
Figure 5.2. 
 




Another water phantom plan was also made in the TPS, without using DICOM image 
files. Further description, as well as results, of this plan can be found in Appendix B  
 
5.3.2 L-shaped PTV in water 
While the cube in water could reasonable indicate if the optimization process was 
working or not, it is a symmetric volume and would therefore not provide us with 
information about potential problems with rotations of the coordinate systems. As we 
have many files which have to be rotated correctly, it would be useful to also test the 
optimizer on a shape which is asymmetric. New plans were therefore made for a water 
phantom with a PTV shaped like an L, hereby denoted L-PTV. The plan also included 
a small OAR placed next to the L-PTV. The L-PTV was defined for this master project 
in the Eclipse TPS alongside three separate plans. Each of these three separate 
treatment plans had different fields, and will be described below. 
The first plan (Plan 1) consists of one field, coming in the lateral direction of the L-
phantom (Figure 5.3). This field is common for all three L-phantom plans. 
The second plan (Plan 2) consists of two perpendicular fields, where the first enters in 
lateral direction, while the second field enters in inferior direction, which is 
perpendicular to the first field. 
The third plan (Plan 3) also consists of two fields, where the first field enters in the 
lateral direction of the L-phantom, while the second field enters from a gantry angle of 
293° and treatment table rotation of 60°. This field is denoted angular field. The reason 
for the second angle is to map how the PTV, OAR, voxels, and fields are rotated in the 
optimization process. Figure 5.3a shows an illustration of the L-phantom with PTV and 
OAR, with the common beam direction while Figure 5.3b shows the three different 




Figure 5.3 a) shows the water phantom, PTV, OAR, and the common beam 
direction for all plans. The water phantom is given in turquoise, the PTV in 
red and the OAR in blue. b) The three different plans in three planes, (i) 
axial, (ii) coronal and (iii) sagittal. The colors indicate the dose level from 
high (red) to low (blue), as described. 
5.3.3  Patient plan 
A patient case was also included in this study. The case was a pituitary adenoma and 
the original plan was optimized to give a homogenous dose of 54 Gy(RBE) to the PTV, 
with 1.8 Gy(RBE) in each fraction The original plan was an IMRT plan, meaning a 
homogenous RBE-weighted dose were not given by each field, but by the sum of the 
two fields. It was therefore of interest to optimize only one of the field and compare to 
the original plan. The re-optimization was done with respect to the WED model 
and RBE1.1. The original treatment plan, with an illustration of the different fields can 
be viewed in Figure 5.4. Here the patient is seen from above where the blue outline 
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represents the PTV. The red arrow represents field 1, and was the field optimized in 
this project.  
 
Figure 5.4 Original plan for patient, with the two fields drawn as arrows. Red 
arrow represents field 1, and green represents field 2. This figure comes 
from the Eclipse TPS. 
5.4 RBE-models 
In this project, three variable RBE-models were used; the model by Wedenberg et al. 
[58] (WED), the model by Unkelbach et al. [50] (UNK), and the non-linear model by 
Rørvik et al. [44] (ROR). They all model the RBE using LET as input parameters. In 
addition to these, the WED and ROR use the 𝛼𝑥/𝛽𝑥 for photons as input parameter to 
account for RBE variations with tissue type. While UNK and WED use the 𝐿𝐸𝑇𝑑, ROR 
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use a non-linear dependency of RBE on LET, and therefore utilize the LET spectrum 
as input parameter instead of 𝐿𝐸𝑇𝑑 [50].  
The WED suggests that the parameter 𝑅𝐵𝐸𝑚𝑖𝑛 equals 1, while the 𝑅𝐵𝐸𝑚𝑎𝑥 depends 
on the LETd and the (𝛼 𝛽⁄ )𝑥 as follows: 
Wedenberg et al. were interested in the linear dependency of the (𝛼 𝛽⁄ )𝑥 and the 𝐿𝐸𝑇𝑑. 
They studied multiple cell-lines and used linear regression to establish a model.  
ROR is based on a non-linear dependency between the RBE and LET. As for the WED, 
the RBEmin = 1, but for the RBEmax, ROR is based on a biological weighting function 
(BWF) which is derived from in vitro cell experiment. The BWF (𝑟𝑚𝑎𝑥(𝐿)) weights 
the LET-spectrum (𝑑(𝐿)). The RBE is written as written as: 
 
 
𝑅𝐵𝐸𝑚𝑎𝑥(𝐿𝐸𝑇𝑑 , (𝛼 𝛽⁄ )𝑥) = 1 +
0.434 Gy(keV μm⁄ )-1
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UNK is not an explicit biological model for RBE calculation, but primarily a model for 
LET optimization. It is based on the principle of an RBE which is linear dependent of 
the LET, and a mean RBE of 1.1 across the SOBP. The RBE can therefore be 
formulated as: 
By setting 𝑅𝐵𝐸𝑚𝑎𝑥 = 𝑅𝐵𝐸𝑚𝑖𝑛 = 𝑅𝐵𝐸 = 1 + 0.04(𝑘𝑒𝑉 𝜇𝑚⁄ )
−1𝐿𝐸𝑇𝑑, a RBE model 
in our formalism is created. In contrast to ROR and WED, UNK is not fitted to in vitro 
data to find the absolute RBE value, and is independent of dose. 
The cell-line used in this project is V79, also used by Wilkens [59], which gives an 
(𝛼 𝛽⁄ )𝑥 =  3.76.
 𝑅𝐵𝐸 = 1 + 0.04(𝑘𝑒𝑉 𝜇𝑚⁄ )−1𝐿𝐸𝑇𝑑 (5.3) 
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6. Results  
6.1 Cubic PTV in water 
Figure 6.1 shows the dose distribution for each model after optimization of their 
respective RBE-weighted plan, on a plane in the center of the PTV. The plot shows 
that for all variable RBE models, the PTV receives a reasonable homogenous RBE-
weighted dose of 2 Gy(RBE). This can also be seen from Figure 6.3 where the solid 
lines indicate the distribution of biological dose in the PTV. This shows that the dose 
to the PTV was between 1.9 and 2.1 Gy(RBE) for the whole PTV. These results 
indicate that the plans have been correctly optimized with all RBE models. 
A comparison between the physical dose of the plan optimized with constant RBE of 
1.1 and with the plans optimized with variable RBE-models can be seen in Figure 6.2. 
The physical dose from the variable RBE optimized plans (shown in the left column of 
the figure) has been subtracted from the physical dose from RBE1.1 plan (top row). The 
dose difference (right column) indicates that the physical dose for the variable RBE-
models are generally lower than with RBE1.1. 
In addition to the RBE-weighted DVHs, Figure 6.3 also shows the DVHs for their 
corresponding physical doses (dashed lines). While RBE-weighted doses are very 
similar, we can observe clear variations in the physical doses. The dose from the WED 
optimized plan is the overall lowest physical dose, indicating that this model predicts 
the highest RBE. On the other hand, the plan optimized with RBE1.1 gives the highest 
dose. The mean, minimum and maximum physical and RBE-weighted dose for the 
PTV is included in Table 6.1.  




Figure 6.1 RBE weighted dose distributions for different biological models (a-
d) and physical dose distribution (e) for the plan optimized only with respect 
to physical dose. All plans are optimized for 2 Gy(RBE) for RBE models and 






Figure 6.2 Comparison of the physical dose from plans optimized with a 
variable RBE model and constant RBE. The plots b,d and f show the RBE-
weighted dose, while the c,e and g show the difference compared to the 
𝑅𝐵𝐸1.1 optimized plan. Dose below 1.2 Gy is set as transparent (left plots), 





Figure 6.3 DVHs of RBE-weighted dose (solid lines), and respective physical 
dose (dotted lines) for the plans optimized with respect to RBE-weighted 
dose. A DVH for the plan optimized with respect to physical dose is also 
given as PHYS. The metrics for the physical doses and RBE-weighted doses 
is given in Table 6.1. 
 
Table 6.1 Dose metrics for RBE-weighted doses in Figure 6.3. The 
corresponding physical doses are given in parenthesis. 
Model Mean dose Min dose Max dose 
 [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) 
WED 1.98 (1.60) 1.61 (1.23) 2.13 (1.75) 
𝐑𝐁𝐄𝟏.𝟏  1.99 (1.81) 1.64 (1.50) 2.11 (1.92) 
UNK 1.98 (1.71) 1.61 (1.34) 2.13 (1.85) 
ROR 1.99 (1.72) 1.64 (1.35) 2.13 (1.86) 
1-D plots of the comparison of the physical doses from the RBE models are presented 
along the beam direction in Figure 6.4 and lateral direction in Figure 6.5. For the depth-
dose plot, three different positions on the SOBP have been marked, and the different 
values can be found in Table 6.2 It is apparent that the biological dose is approximately 
2 Gy(RBE) along the entire depth from 13-17cm in water for all plans. It can also be 
seen that the physical dose to the respective RBE-weighted models is generally lower 
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compared to the biological dose, i.e. the RBE is above 1, which is expected. The 
physical dose from the variable RBE-models have similar shape, and while the WED 
gives the lowest physical dose of these, UNK and ROR model deliver slightly higher 
and similar physical dose.   
A comparison of the biological doses for a plan optimized for physical dose was also 
made and is presented in Figure 6.6. There it can be seen that the shape of the biological 
dose for the variable RBE-models is similar but vary in magnitude. The RBE-weighted 
dose from WED is higher the two other models, while UNK is higher again than ROR. 
This result is not the same as previously seen, as UNK and ROR is observed to be 




Figure 6.4 Physical dose (dashed lines), for the different plans optimized 
with respect to RBE-weighted dose (solid lines) in depth dose direction. 
Three different areas of the SOBP is marked, and their respective values are 




Figure 6.5 Physical dose (dashed lines), for the different plans optimized with 
respect to RBE-weighted dose (solid lines) in lateral direction. 
 
Table 6.2 Physical dose in different regions in the depth dose profiles for the 
four biological dose plans given in Figure 6.4 at three locations along the 
SOBP. The percent values in the parenthesis are the physical dose 
compared to the 𝑅𝐵𝐸1.1 plan. 
Dose (Gy) Region 
Model SOBP1 SOBP2 SOBP3 
𝐑𝐁𝐄𝟏.𝟏  1.80 1.82 1.79 
WED 1.65 (92 %) 1.62 (89 %) 1.48 (83 %) 
ROR 1.76 (98 %) 1.74 (96 %) 1.61 (90 %) 





Figure 6.6 Comparison of RBE-weighted dose of a plan optimized with 
respect to physical dose of 2Gy in beam direction (left) and lateral direction 
(right). 
6.2 The L-PTV in water 
6.2.1 Single field plan 
Figure 6.7 shows the RBE-weighted dose distributions for the single field plan. It can 
be observed that the PTV (outlined in red), received a homogenous dose of 
approximately 2 Gy(RBE) for all models. As for the cubical PTV, this indicates again 
the correctness of the optimization process for all models. It can also be seen that the 
OAR (outlined in pink), receives a small dose at the edge closest to the PTV. The same 
results can also be seen from the DVHs (Figure 6.9). The dose metrics (Table 6.3 and 
Table 6.4), also shows that the minimum RBE-weighted dose varied between 1.63 and 
1.83 Gy(RBE), while the maximum RBE-weighted dose were between 2.14 – 2.23 
Gy(RBE). 
Figure 6.8 shows the physical doses from the respective RBE models and the difference 
between the RBE1.1 dose and the variable RBE models. It can be observed that the 
physical dose from the variable RBE-models is lower than for the plan with constant 
RBE, with the highest differences at the distal end of the beam. This is also indicated 
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by the DVHs (Figure 6.9), and the belonging DVH metrics (Table 6.3 and Table 6.4), 
where the mean physical dose to both the PTV and OAR for the variable RBE-models 
are smaller than for the RBE1.1 plan. This is similar as dose distribution to the cubical 
PTV. The plots from the optimizer can be found in Appendix D . 
 
 
Figure 6.7 RBE weighted dose distributions for different biological models (a-
d) and physical dose distribution (e) for the plan optimized only with respect 
to physical dose. All plans are optimized for 2 Gy(RBE) for RBE models and 
2 Gy for the physical dose. The PTV is outlined in red and the OAR is 




Figure 6.8 Comparison of the physical dose distributions from a plans 
optimized with a variable RBE model and constant RBE. The plots b,d and f 
show the RBE-weighted dose, while the c,e and g show the difference 
compared to the 𝑅𝐵𝐸1.1 optimized plan (a). Dose below 1.2 Gy is set as 
transparent (left plot), while dose differences (right plot) only show between 





Figure 6.9 DVHs of RBE-weighted dose (solid lines), and respective physical 
dose (dotted lines) for the plans optimized with respect to RBE-weighted 
dose. The lines marked with squares represents the RBE-weighted dose 
and the physical dose the OAR. The PTV and OAR metrics for the physical 
doses and RBE-weighted doses is given in Table 6.3 and Table 6.4. 
 
Table 6.3 DVH metrics for the L-PTV plan with a single field. The table 
displays the RBE-weighted doses belonging to the PTV, and the belonging 
physical doses in parenthesis. 
Model Mean dose Min dose Max dose 
 [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) 
WED 1.99 (1.60) 1.78 (1.30) 2.21 (1.73) 
𝐑𝐁𝐄𝟏.𝟏  2.01 (1.82) 1.63 (1.48) 2.14 (1.94) 
UNK 1.96 (1.71) 1.76 (1.39) 2.19 (1.83) 
ROR 2.03 (1.72) 1.83 (1.43) 2.23 (1.85) 




Table 6.4 DVH metrics for the L-PTV plan with a single field. The table 
displays the RBE-weighted doses belonging to the OAR and the belonging 
physical doses in parenthesis. 
Model Mean dose Min dose  Max dose  
 [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) 
WED 0.42 (0.26) 0.002 (0.001) 1.64 (1.20) 
𝐑𝐁𝐄𝟏.𝟏  0.32 (0.29) 0.001 (0.001) 1.45 (1.36) 
UNK 0.35 (0.28) 0.001 (0.001) 1.56 (1.28) 
ROR 0.41 (0.28 0.001 (0.001) 1.63 (1.29) 
PHYS 0.32 0.001 1.49 
6.2.2 Two perpendicular fields  
Figure 6.10 shows the biological dose for the treatment plan with two perpendicular 
fields. It can be observed that the PTV (marked red), receives a homogenous dose of 2 
Gy(RBE), while the OAR (marked pink) receives a small dose at the edge close to the 
PTV. This is also supported by Figure 6.12, which shows a DVH for the PTV and for 
the OAR, and the belonging RBE-weighted and physical doses. There it can be see that 
the median dose lies around 2 Gy(RBE), while the OAR receives a maximum of 1.2 
Gy(RBE), dependent on the model. This is also seen in the belonging dose metrics in 
Table 6.5, which gives the mean dose for the DVH to be approximately 2 Gy(RBE) for 
the RBE-weighted doses, and 2 Gy for the plan optimized with respect to physical dose. 
Figure 6.11 shows the physical dose distributions (a,b,d and f) belonging to the RBE-
weighted dose plans and the dose difference (c,e and g) between the variable RBE 
models and the plan with constant RBE of 1.1. It can be observed that the physical dose 
from the variable RBE models are lower than for the RBE1.1, and the difference is 
evenly distributed over the PTV, contrary to the dose distribution from the single field 
L-PTV and cubic PTV. The difference is also supported by the DVH (Figure 6.12), and 
the metrics for physical doses to both PTV and OAR (Table 6.5 and Table 6.6), which 
suggest lowest physical dose from WED, while UNK and ROR are similar. The plots 






Figure 6.10 RBE weighted dose distributions for different biological models 
(a-d) and physical dose distribution (e) for the plan optimized only with 
respect to physical dose. All plans are optimized for 2 Gy(RBE) for RBE 
models and 2 Gy for the physical dose. The PTV and OAR are outlined in 
red and pink, respectively. The red arrow shows the direction of the first field, 





Figure 6.11 Comparison of the physical dose distributions from a plans 
optimized with a variable RBE model and constant RBE. The plots b,d and f 
show the RBE-weighted dose, while the c,e and g shows the difference 
compared to the 𝑅𝐵𝐸1.1 optimized plan (a). Dose below 1.2 Gy is set as 
transparent (left plot), while dose differences (right plot) only show between 




Figure 6.12 DVHs of RBE-weighted dose (solid lines), and respective 
physical dose (dotted lines) for the plans optimized with respect to RBE-
weighted dose. The lines marked with squares represents the RBE-weighted 
dose and the physical dose the OAR. The PTV and OAR metrics for the 
physical doses and RBE-weighted doses is given in Table 6.5 and Table 6.6. 
Table 6.5 Dose metrics for the L-PTV plan with two perpendicular fields. The 
table displays the RBE-weighted doses belonging to the PTV, and their 
respective physical doses in parenthesis. 
Model Mean dose Min dose Max dose 
 [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) 
WED 2.00 (1.61) 1.88 (1.40) 2.20 (1.74) 
𝐑𝐁𝐄𝟏.𝟏  2.02 (1.83) 1.83 (1.66) 2.18 (1.98) 
UNK 2.01 (1.72) 1.88 (1.52) 2.22 (1.86) 
ROR 2.01 (1.73) 1.91 (1.54) 2.21 (1.86) 




Table 6.6 Dose metrics for the L-PTV plan with two perpendicular fields. The 
table displays the RBE-weighted doses belonging to the OAR, and their 
respective physical doses in parenthesis. 
Model Mean dose Min dose Max dose 
 [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) [Gy(RBE)] ([Gy]) 
WED 0.34 (0.24) 0.002 (0.001) 1.42 (1.06) 
𝐑𝐁𝐄𝟏.𝟏  0.28 (0.26) 0.001 (0.001) 1.31 (1.19) 
UNK 0.30 (0.24) 0.002 (0.001) 1.34 (1.12) 
ROR 0.33 (0.24) 0.002 (0.001) 1.39 (1.13) 
PHYS 0.29 0.001 1.32 
 
6.2.3 Two angular fields 
Figure 6.13 shows the biological dose distribution for the treatment plan with two 
angular fields. There it can be seen that most of the PTV (marked red), receives a RBE-
weighted dose of 2 Gy(RBE). This is supported by the DVH in Figure 6.15, which 
displays the DVH of the PTV and OAR. It can be observed that the minimum dose for 
the PTV is around 1.5 Gy(RBE) which is the lowest for all water phantom plans. The 
maximum RBE-weighted dose to the OAR is around 1.4 Gy(RBE), which is the highest 
of all the three L-PTV plans.  
Figure 6.14 shows the difference between in physical dose distribution between the 
variable RBE models and RBE1.1. The results are quite similar as for the two other L-
PTV plans, where the dose from WED is lower than from ROR and UNK. This is also 
supported by the DVH (Figure 6.15) and dose metrics (Table 6.7 and Table 6.8). The 
largest difference is observed at the distal end of the PTV similar to the single fields 
plan for the L-PTV and the cubic PTV. The plots from the optimizer can be found in 





Figure 6.13 RBE weighted dose distributions for different biological models 
(a-d) and physical dose distribution (e) for the plan optimized only with 
respect to physical dose. All plans are optimized for 2 Gy(RBE) for RBE 
models and 2 Gy for the physical dose. The PTV and OAR are outlined in 
red and pink, respectively. The red arrow shows the first field, while the 
green arrow shows the second field. Note that the second field also comes 




Figure 6.14 Comparison of the physical dose distributions from a plans 
optimized with a variable RBE model and constant RBE. The plots b,d and f 
show the RBE-weighted dose, while the c,e and g shows the difference 
compared to the 𝑅𝐵𝐸1.1 optimized plan (a). Dose below 1.2 Gy is set as 
transparent (left plot), while dose differences (right plot) only show between -




Figure 6.15 DVH of the different biological models for the plan with two 
angular fields. Solid lines represent the PTV while the dotted lines 
represents the OAR. The dose metrics can be found in Table 6.7 and Table 
6.8. 
 
Table 6.7 Dose metrics for the L-PTV plan with two angular fields. The table 
displays the RBE-weighted doses belonging to the PTV, and their respective 
physical doses in parenthesis. 
Model Mean dose Min dose  Max dose  
 [Gy(RBE)]([Gy]) [Gy(RBE)]([Gy]) [Gy(RBE)]([Gy]) 
WED 1.99 (1.61) 1.39 (0.97) 2.27 (1.90) 
𝐑𝐁𝐄𝟏.𝟏  1.99 (1.81) 1.27 (1.15) 2.33 (2.12) 
UNK 1.99 (1.71) 1.30 (1.05) 2.32 (2.02) 
ROR 1.99 (1.72) 1.36 (1.05) 2.28 (2.02) 




Table 6.8 Dose metrics for the L-PTV plan with two angular fields. The table 
displays the RBE-weighted doses belonging to the OAR, and their 
respective physical doses in parenthesis. 
Model Mean dose Min dose  Max dose 
 [Gy(RBE)]([Gy]) [Gy(RBE)]([Gy]) [Gy(RBE)]([Gy]) 
WED 0.56 (0.38) 0.008 (0.004) 1.65 (1.25) 
𝐑𝐁𝐄𝟏.𝟏  0.46 (0.42) 0.005 (0.005) 1.51 (1.38) 
UNK 0.48 (0.40) 0.005 (0.004) 1.59 (1.33) 
ROR 0.53 (0.41) 0.006 (0.004) 1.62 (1.33) 
PHYS 0.46 0.005 1.51 
6.2.4 Patient plan 
Figure 6.16 shows the original RBE1.1 dose distribution for field 1 of the patient plan 
(a), as well as the two plans optimized with respect to RBE1.1 (b) and WED (c). The 
fields are normalized to visualize the homogenity of the fields, and not to absolute dose, 
meaning the doses viewed are only for illustrational purposes. It can be seen that the 
original field is inhomogenous and that the dose is not only deposited in the PTV 
(outlined in blue); the original plan has a hotspot below the PTV. For the two optimized 
plans, the dose distribution is more even than for the original plan, but also results in 
dose outside the PTV. The optimized plans also have a hotspot of dose similar to the 
original plan outside the PTV. The results indicates that the optimizer works for a 




Figure 6.16 Comparison of dose distribution for the original plan for field 1 
(a), and the two optimized plans (b and c). Note that these fields are 
normalized to look at homogeneity in the dose distribution and not according 






In this project, a prototype optimizer has been used together with the FLUKA MC-
code to re-optimize treatment plans with respect to different RBE-models. A thorough 
method has been made for the use of the optimizer, and the optimized results have been 
verified for four different plans; one for a cube-shaped target in a water and three for 
an L-shaped target in water. A single field uniform dose (SFUD) optimization of a 
patient plans has also been done. The dose distributions of the different treatment plans 
have been compared, with respect to the physical dose. The results indicate that for all 
treatments plans, the PTV achieved the prescribed RBE-weighted dose of 2 Gy(RBE) 
for all biological models, which indicates that the optimizer works well as no errors 
were observed for either of the phantoms.  
The general trend showed that the WED model provided the lowest physical dose, 
while UNK and ROR provided similar dose distributions to the PTV. The WED model 
resulted in a physical dose which was generally 11% lower than the physical dose from 
plans optimized with RBE1.1, while UNK and ROR was about 6% lower. The general 
problems that occurred and was solved during this project consisted of making the in-
house dose verification tool compatible with the requirements of the optimizer and 
vice-versa.  
7.1 Optimization process 
For the cube-shaped water phantom, the treatment plans optimized with both RBE-
weighted dose and physical dose delivered a seemingly homogenous biological dose 
of 2 Gy(RBE) to the entire volume. This is supported by the DVHs, which suggests a 
mean dose around 2 Gy(RBE) and 1D plots, which shows a SOBP around 2 Gy(RBE) 
in the area of the PTV. The optimizer works therefore well with the water phantom.  
For the L-phantom, three separate plans were made; one field, two perpendicular fields, 
and two angular fields. All three were tested with the same biological models as for the 
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first water phantom. The first plan (one field) was optimized well, and the results 
showed an even dose of 2 Gy(RBE) for all models. The DVH for this plan is not as 
good as for the first water phantom, but sufficient as the median biological dose is 2 
Gy(RBE). It is not always physical possible to achieve a perfect DVH to the PTV while 
also sparing the OAR, especially with a single field. A middle-course is often needed 
in the treatment planning process. 
For the plan with two perpendicular fields, the results showed, as with the single field 
plan, a homogenous RBE-weighted dose of 2 Gy(RBE) to the PTV, and no elevated 
values in the OAR, which means the optimizer also works well with two fields. The 
DVH showed better results than for the L-phantom with one field, which was expected 
as the field positioning in this plan provided a better basis for homogenous dose 
throughout the PTV. 
For the plan with two angular fields, the result showed that most of the PTV received 
a biological dose of 2 Gy(RBE), while the top of the L, received somewhat less dose. 
This might come from the unpractical field positioning, as this particular plan was 
made to test different angles to optimize with and to test the ROI positioning, and not 
to get the best possible clinical plan. However, the DVH showed a median dose around 
2 Gy, which means that most of the PTV received sufficient dose. It can, however, be 
observed that the minimum dose is around 1.5 Gy(RBE), which is the lowest of the 
four plans.  
By comparing the DVH from the L-phantom plans, with the output from the optimizer, 
found in Appendix D , it can be seen that the DVHs are similar. This is also an 
indication that the optimizer works well and the method is functional.  
The optimizer was also tested on a patient plan, where one field from the patient plan 
was optimized to see if better dose distribution could be achieved. The result showed 
that the dose from field 1 in the original plan was not homogenous, and some of the 
dose was outside of the PTV. The optimized results showed a more homogenous dose 
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distribution, although, as also seen in the original field, some of the dose was 
distributed outside the PTV. The shape of the dose distribution also indicates that the 
results from the optimizer are shifted, meaning the PTV was misplaced or shifted in 
the optimizer. Although the results from the patient plan are preliminary, the 
homogenous dose distribution from the two plans shows the potential of using the 
optimizer on clinical patient cases. 
During this work it appeared that the ROI-files (information about which region to 
score) had a different rotation than the phantom/patient. As a result, a method for 
rotating the patient and the ROI-files to orientations corresponding to the new beam 
directions had to be developed. This problem might arise from the script 
HUchanger.py, which provides information about the voxel location for the different 
ROIs.  
Another problem that occurred was statistical errors. For plans with large spot-spacing 
(distance between each pencil beam spot) and low number of pencil beams, higher 
statistics were needed. The spot spacing used for a water phantom at CNAO was 2 mm 
for carbon ions, while for the water phantom used in this project had a spot spacing of 
5 - 4 mm. This it might impact the optimization process, as it could be easier for the 
optimizer to have more spots within the volume to optimize. This is supported by Fjæra 
et al. [60], which suggests that larger spot spacing may lead to an additional dose 
outside the PTV for the same optimization problem.  
7.2 RBE model dose difference 
Comparing the dose distribution from the different optimization strategies, shows that 
optimizing with a variable RBE-model will give lower physical dose to PTV than for 
the method which is clinically applied today (RBE1.1). The mean physical dose from 
the WED plan was around 1.60 Gy for all plans, which is 89% of the physical dose 
from the RBE1.1 plan (1.8 Gy). For the UNK and ROR plans, the mean physical dose 
was around 1.73 Gy which is about 95% of the physical dose from the RBE1.1 plan. 
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Similar results have been produced by Rørvik et al. [61], where considerable 
differences between RBE and RBE-weighted doses from different RBE models is 
found. The difference in physical dose distribution is, however, not homogenous in the 
PTV, as observed, and it is more correct to look at the dose differences in certain areas 
in the PTV. The general trend for all plans is a higher physical dose difference at the 
distal end of the beam between the variable RBE plans and RBE1.1 plan. In the cubic 
PTV plan, the physical dose varies 10% from the start of the PTV until the distal end. 
Grün et al. [62] suggested that the RBE-weighted dose is highest at the distal end of 
the beam, and could lead to a dose extension. This result is similar to the theoretical 
water phantom in Appendix B where physical doses from different variable RBE plans 
also were compared.  
The dose difference is, however, more homogenous in the plan with two perpendicular 
fields, with no larger differences at the distal part of the beam. This might come from 
that the physical dose from the perpendicular fields evens some of the physical dose 
distribution out, and is not visible as the field goes into the plane, and therefor leaving 
the distal part of the beam not visible.  
The minimum and maximum doses varies from plan to plan, where the smallest 
deviation came from the L-PTV plan with two perpendicular fields where it was 
observed an average minimum and maximum RBE-weighted dose of 1.87 and 2.2 
Gy(RBE), respectively. This was expected as it originally provided a good basis for 
treatment planning with its perpendicular fields. The largest deviation came from the 
L-PTV plan with angular fields, where it was observed an average minimum and 
maximum RBE-weighted dose of 1.32 and 2.31 Gy(RBE), respectively. This comes 
from the unpractical second field which might provide a bad basis for homogenous 
dose to the PTV. 
Overall, there is indication that using RBE-models can give a lower dose overall, 
reducing risk of side effects while still delivering the same biological dose. The 
variable RBE models also deviate between themselves, as physical dose from UNK 
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and ROR is generally higher than WED. This gives rise to the uncertainty that applying 
variable RBE models in clinical proton therapy might lead to under dosage in the tumor 
volume. This is also supported by Paganetti et al. [49], which suggests that the clinical 
RBE of 1.1 is sufficient for now. Finally, the differences suggest that there is lot of 
uncertainty in the field of RBE models, and more research should be done in this field, 
before any RBE models is applied clinically.  
7.3 Suggestions for further work 
After creating a method for optimizing treatment plans with respect to RBE-weighted 
dose, the possibilities opens up to view physical dose distributions in multiple ROIs, 
when optimizing with respect to RBE-models. This could provide insight in the effects 
of RBE-models and help shed a light on the clinical use of RBE models. 
Another project would be to implement the optimizer method to the already existing 
dose verification tool at University of Bergen. The method for using the optimizer is 
still dependent on manual copy-paste, which should rather be replaced with scripts. 
This will rule out any potential errors that can occur during this manual process. The 
script HUchanger.py should also be included in this process, but initially checked for 







In this project, a method for the use of an optimizer together with the FLUKA MC code 
has been developed and tested on proton therapy treatment plans, applying variable 
RBE-models. The method is based on an existing tool for reading and translating data 
from DICOM files, but most scripts are either rewritten or created to match the 
requirements of the optimizer.  
Dose estimates of the optimized plan showed that the method was successful, and 
provided a good dose conformity for the models used in the different water phantom 
treatment plans. Promising results were also achieved from a patient plan involving 
optimization of a single field. 
The results showed that the physical dose was reduced, typically on average 6 to 11% 
from variable RBE models compared to RBE1.1. This shows the impact of biological 
optimization and indicates that the treatment plans optimized with RBE1.1 might deliver 
too high biological dose to the target, in particular in the distal part. Biological 
optimization could therefore reduce the dose to the healthy tissue in general, and 
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Appendix A  Tables with descriptions belonging 
to method 
In Table A.1, Table A.2 and Table A.3, the description belonging to the different steps 
in method can be found, with a short description of their role in this project. 
Table A.1 Information about the files and scripts for the initial FLUKA 
simulation. 
File/script Information Role in master project 
Output from TPS Information about the CT-scans, 
the regions of interest and the 




but helped making one 
of the plans of one of 
the phantoms (the L-
phantom, described 
later) 
Sort_dicom.py Converts information from the 
DICOM-files into FLUKA-input 
files 
Received script, did 
minor changes 
Source.f Information about beam source Received script, did 
minor changes 
Fluscw.f Information about beam weighting Received script, did 
minor changes 
Input file Input file for FLUKA Received script, did 
minor changes 
Voxelfile Information about the voxels in 
the phantom 
Used standard scripts 
to create the VOXEL 
files from the DICOM-
files 
Information about 
pencil beam (datfile) 
Information about the different 





Script used to modify source and 
input files 
Used this script to 
make source and input 
file for each simulation 
Split_datfile.py Script used to modify the datfile 
and create files for optimizer. 
Used this script to 
make datfile and raster 







Table A.2 Overview of files and scripts used for the optimizer and for the 
FLUKA simulation for dose verification 




The script HUchanger.py reads in 
DICOM files, and gives out 
information about region of 
interests (ROIs) 
Received script, did 
minor changes 
Information about 
PTV and ROI 
Information about dose and 
constraints for the different 
region of interests (ROIs) 
Output from HU-
changer 
Optimizer C++ based optimizer Received script. 
Major part of the 
master project was to 
understand how the 
optimizer worked and 
how to use it 
Information about 
new weighting 
The output from the optimizer, 
with information about the new 
weightings of the pencil beams 
Used the weighting 
for dose verification 
Make_reopt_datfile.py Script which changes the 
weighting from the original plan 
to the weighting for the optimized 
plan 
Python script made 
during master project 
FLUKA simulation 
with re-optimized data 
Simulation with optimized plan Put all the scripts 





Table A.3 Overview of scripts and files used after the dose verification 




Converts the files from the 
FLUKA simulation into DICOM 
files 
Received script, did 
minor changes 
Plot_1d_results.py Script which plots the results in 
1D 
Python script made 
during master project 
Slicer Software which reads in DICOM-
files and provides dose volume 
histograms (DVHs) 
Software 
Plot_dicom.py Plots 2D dose distribution Received script 
DVH Dose volume histogram (DVH) Table with dose 
volume histogram 
(DVH) provided from 
Slicer, plotted using 
python script made for 
master thesis 
2D plot 2D results provided from 
plot_dicom.py 






Appendix B  Results from theoretical water 
phantom 
A plan for a water phantom without DICOM-files was also made, where the plan was 
instead made completely theoretical, where the spot spacing and energy layers were 
predetermined. The results are given in Figure B.0.1, while a depth dose profile is given 
in Figure B.0.2. 
 
 
Figure B.0.1 Comparison of physical- (solid lines) and biological dose 
(dotted lines) distributions for plans optimized with different biological 
models, for the entire dose profile (above) and zoomed in on the Spread Out 




Figure B.0.2 Depth dose for the 𝑅𝐵𝐸1.1optimized plan plotte together with the 





Appendix C  Extended method for the use of 
optimizer with protons 
Introduction 
This document describes in detail how to use the optimizer for proton beams. To 
summarize the process, first a FLUKA-simulation is ran with the original pencil beam 
weighting, before running the optimizer. The optimizer will then optimize the 
weightings of the pencil beams. This result is then used in a second FLUKA simulation 
to verify the result. 
Scripts and properties 
This section contains information about the scripts used in the method and how to 
modify them. 
Scripts and files used for first simulation 
 Sort_dicoms_for_optimizer.py 
◦ Modified script for this thesis which creates datfiles with information about 
the pencil beams. The new pencil beams have no divergence (the angle is 
constant for all pencil beams), which also only have one direction (z-
direction). The directions to use this script are prompted. 
 HU-changer.py 
◦ Script which creates ROI-files for the optimizer. Originally made at CNAO 
 create_datfiles.py 
◦ This script creates chosen number of dat-files with the original pencil beam 
weighting obtained from TPS. The script has to be modified for each field. 
This is done at the bottom of the script, where the filename of the original 
datfile is written, along with the number of desired files. 
 create_input_and_source.py 
◦ This script makes source files and input files for the FLUKA-simulation. It 
is important the original input file and source file is in the same folder, and 
since these filenames are read in the script, these names must match as in 
the bottom of the script. Here, you must change the number of the desired 
files, also done in the bottom of the script.  
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◦ The input file which is going to be used must also be modified. The 
number of primary particles must be changed to the desired number of 
primaries, and all cards for scoring region must be removed, and replaced 
with the line #include SCORING.flk. 
 SCORING.flk 
◦ Scoring card for the simulation. This script needs to be changed according 
to gantry angle and patient support angle (it is commented in the script  
where this has to be done). These angles can be found in the DICOM-files. 
(use script read_dicom.py, and find the lines labelled gantry angle and 
patient support angles). 
 compile_protons.sh 
◦ This script compiles executables for the FLUKA-simulation. Modify the 
first line to match the number of input files that is going to be used. In our 
simulations the fluscw-routine and source-routine is used. 
 proton_run.sh 
◦ Script to start the FLUKA simulation in the terminal. Before running, it is 
important to modify the first line to match the number of input files that is 
going to be used. 
Scripts and files used for the optimizer 
 do_optimization.sh 
◦ Starts optimization for the four models: Wedenberg, Unkelbach, Rørvik 
and RBE = 1.1. It also starts physical optimization. This script starts a 
number of subscripts, which all needs to be modified. An example of this 
subscript is 2_proton_biological_optimzation_wed.sh 
◦ 2_proton_biological_optimzation_wed.sh and other scripts for the different 
biological models 
▪ For all these files (labelled with a number in the start of its name), 
needs to be changed. For a single field a single address line is given at 
the top. This address needs to the folder with the simulation files 
(example fort.50). Secondly, make sure the correct PTV is addressed 
(line labelled –fileroi), and make sure the PTV and OAR files is in the 
optimizer folder. Check also that the fort-files matches for each model 
 create_optimizer_scripts.py 
◦ Python scripts which makes scripts to run the optimizer with different 
models and different fields. The first lines in the script represent the 
choices available. NB, this script makes shell scripts (.sh), and permission 
to run this script can be denies. The command “chmod u+x filename” must 





Scripts and files used after the optimization 
 create_new_dat_file.py 
◦ Makes a new datfile with the new weightings from the optimizer. It is 
important that the two filenames in the bottom of the script matches the file 
from the optimizer and the file with similar weighting 
(nyfil_fra_FLUKA_lik_vekting.dat). 
 fluscw_IFT.f and source_IFT.f 
◦ Subroutines used in FLUKA, don’t need any changes if the files in the 
attached folder is used. 
 SCORING.flk 
◦ Scoringcard for the reoptimization process. The volume scored needs to be 
modified, so the dimensions is similar to the original inputfile. 
Procedure 
Before use, a folder containing all the files should be made for each field, where the 









 optimizer folder labeled “optimizer”, containin listed files 
◦ do_optimization.sh 
◦ create_optimizer_script.py 
◦ The optimizer scripts 
◦ ROIs 
 
This folder will be denoted field_x, which represents each field. 
 
1. FLUKA simulation with equally weighted pencil beams 
 
NB: Before use, the files listed in “Scripts and properties”, section needs to be modified 
according to the directions given above. 





To get the original plan, use the script 
python sort_dicoms_no_divergence 
in a folder containing the same DICOM files. Two folders should have been made 
now, one containing the files needed for the optimization of the treatment plan, and 
one folder with the files for the original treatment plan. 
Enter the folder containing the files needed for the optimization and copy the dat-files 
for each field into the folder field_x. In the folder field_x modify the scripts as listed 
in the start of this document. 
The next step is to run the FLUKA simulation. This is done by running the command: 
./proton_run.sh 
in the terminal. This command compiles the files and starts the FLUKA-simulation.  
 
2. Running the optimizer with the output from the FLUKA simulation 
 
After the initial simulation, the results are given as fortran files belonging to the binning 
scored e.g. xx_fort.50 if bin 50 is scored. These are going to be read in by the optimizer 
along with the rasterfiles and region of interest. Enter the optimizerfolder which should 
lie in the same folder as the results from the initial simulation. Check that all parameters 




This will create the shell scripts for running the optimizer with chosen biological 








The names in the parenthesis represents the options, of models and number of fields, 
e.g. the use of the Wedenberg model and two fields will therefore be: 
./2_proton_biological_optimization_wed_two_fields.sh 
This command will run the optimizer, and folders with the different results will be 
made. 
In these folders, files named pb_xx.res are created from the optimizer, which contains 
the new information about the pencil beams. Multiple plots are also created including 
DVHs, which can be used to verify if the optimization process has succeeded, and if 
the results looks OK.  Copy the selected .res file (The final res file is called 
pb_final.res) into the folder for the FLUKA-simulation with reoptimized result.  
3. FLUKA-simulation with results from the optimizer 
 
The res file from the optimizer (e.g. pb_final.res), must first be converted into a 





The original datfiles also needs to be included in the folder, and correct filenames 
needs to be at the end of the script. This script also gives out normalization factors for 
the field(s). 
The files created from this script is named “nyfil_for_reopt_i_fluka_bio.dat” or 
“nyfil_for_reopt_i_fluka_bio_field_1.dat”, and must be copied into the folder used 
for the simulation. In the folder for simulation open the inputfile in flair: 
flair (inputfile).inp 
After opening the input file FLAIR, save it as a new project. Choose number of 
primaries at the bottom. Then go to compile, and create and executable by clicking on 
the tab labeled “Executable:”. Save the executable as ex.exe, and add fluscw_IFT.f and 




After the simulation go to tab data and click on process. Then click on files, and data. 
Choose the bnn-files and click on convert to ASCII. Copy these new files 
(filename+bnn.lis), into a new folder called BNNLIS. Open a new terminal in the 
IMPT-folder and run the script 
python convert_to_dicom_with_non_1.1.py 
The user is prompted for the file locations, which models are going to be used, which 
BNN files to use and which normalization method to use. For the latter, choose “3 – 
normalize fields using own factor” and use the normalization factors given earlier to 
normalize each field 




The user will then be prompted of single or comparison plots, file locations, 
normalization factors and use scoring outside the PTV. The user will also be 




















Appendix D  Plots from output of optimizer  
The optimizer provides different plots as output, including cumulative DVHs and slices 
of the ROIs. The results from L-PTV and cubic PTV are found in Figure D.3 to Figure 
D.10. 
 






Figure D.4 Slice of the PTV for the cubic PTV plan. 
 
 
Figure D.5 DVH for plan with L-PTV plan with 1 field. The red line represents 




Figure D.6 Slice of the L-PTV in the middle of the water phantom for the L-
phantom plan with single field. 
 
Figure D.7 DVH for L-PTV plan with two perpendicular fields. The red line 




Figure D.8 Slice of the PTV in the L-PTV plan with angular fields. 
 
Figure D.9 DVH for the L-PTV plan with angular fields. The red line 





Figure D.10 Slice of the L- PTV in the middle of the water phantom for the 
plan with perpendicular fields. 
 
